USFDA reverses status of Aurobindo Pharma Ltd’s general injectable formulation unit

Aurobindo Pharma Ltd has announced in reference to the USFDA inspection of Unit IV, a general injectable formulation manufacturing facility of the company, and issue of Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status by USFDA.
On February 21, 2020, the company received a communication that the inspection conducted by the US Food and Drug Administration (USFDA) at Unit IV, from November 4,2019 to November 13, 2019, is still open and under review, by way of rescindment of 90-day VAI letter that was issued by them on February 18, 2020.